Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13803187 | 1.00 | TSHR (0.44) | TSHRSMN1; SMN2GPBAR1CYSLTR1TAAR1 | |
| SCHEMBL12124933 | 0.87 | TSHR (0.42) | TSHRSMN1; SMN2TAAR1MTNR1AMTNR1B | |
| SCHEMBL12327116 | 0.86 | MAPK1 (0.47) | TSHRSMN1; SMN2GPBAR1CYSLTR1TAAR1 | |
| SCHEMBL13802842 | 0.84 | TSHR (0.45) | TSHRSMN1; SMN2GPBAR1CYSLTR1TAAR1 | |
| SCHEMBL28121129 | 0.84 | CYP4F2 (0.50) | GPBAR1CYSLTR1MTNR1AMTNR1B | |
| SCHEMBL30484265 | 0.84 | DHFR (0.48) | TSHRSMN1; SMN2TAAR1GAAHSD17B10 | |
| SCHEMBL112105 | 0.84 | DHFR (0.48) | TSHRSMN1; SMN2TAAR1GAAHSD17B10 | |
| SCHEMBL16902897 | 0.84 | TSHR (0.47) | TSHRSMN1; SMN2GPBAR1CYSLTR1TAAR1 | |
| SCHEMBL16902900 | 0.83 | TSHR (0.49) | TSHRSMN1; SMN2GPBAR1CYSLTR1MTNR1A | |
| SCHEMBL11665507 | 0.83 | GPBAR1 (0.55) | TSHRGPBAR1CYSLTR1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211904-B2 | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | Merck, Sharp & Dohme Corp. (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1910364-B1 | SPIROPIPERIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2012-03-21 | — | — | EP | disclosed |
| US-7541466-B2 | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases | GENZYME CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK SHARP & DOHME LLC | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021454-A1 | Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease | BACE1, APP, PSEN1 | TSHR 4146/4885SMN1; SMN2 2111/4885GPBAR1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.